Marieke van Rosmalen

General discussion 149 8 REFERENCES 1. Eftimov F, Lucke IM, Querol LA, et al. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 2020;143:3214– 3224. 2. Viala K. Diagnosis of atypical forms of chronic inflammatory demyel inat ing polyradiculoneuropathy: a practical overview based on some case studies. Int. J. Neurosci. 2016;126:777–785. 3. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: Diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J. Neurol. Neurosurg. Psychiatry 2019;90:125–132. 4. IkedaS,KoikeH,Nishi R, et al. Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 2019;90:988–996. 5. Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18:784–794. 6. OaklanderA, LunnM, Hughes R, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews. Cochrane Database Syst. Rev. 2017;13:1–33. 7. Kuwabara S, Misawa S, Mori M, et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy:Afive year follow up of 38 cases. J. Neurol. Neurosurg. Psychiatry 2006;77:66–70. 8. Kuitwaard K, Hahn AF, Vermeulen M, et al. Intravenous immunoglobulin response in treatmentnaïve chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 2015;86:1331–1336. 9. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst 2014;13:2–13. 10. VlamL,VanDer PolWL, Cats EA, et al.Multifocal motor neuropathy: Diagnosis, pathogenesis and treatment strategies. Nat. Rev. Neurol. 2012;8:48– 58. 11. Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–433. 12. van Schaik I, van den Berg L, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst. Rev. 2005;2:920–921. 13. Van Den Berg-Vos RM, Franssen H, Wokke JHJ, Van Den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125:1875– 1886. 14. Van den Berg-Vos RM, Franssen H, Visser J, et al. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J. Neurol. 2002;249:330–336. 15. Taylor B V., Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle and Nerve 2000;23:900–908. 16. Al-ZuhairyA, Sindrup SH, Andersen H, Jakobsen J. A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 2019;24:64– 71. 17. Cats EA, Jacobs BC, Yuki N, et al. Multifocal motor neuropathy: Association of anti-GM1 IgM antibodies with clinical features. Neurology 2010;75:1961–1967. 18. Vlam L, Cats EA, Harschnitz O, et al. Complement activity is associated with disease severity in multifocal motor neuropathy. Neurol. Neuroimmunol. NeuroInflammation 2015;2:1–8. 19. van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory